Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

24.04 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1
Open 24.04
Bid (Size) 22.20 (4)
Ask (Size) 24.00 (1)
Prev. Close 24.04
Today's Range 24.04 - 24.04
52wk Range 8.350 - 41.93
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch
Amylyx Pharmaceuticals is the rare young biotech that's profitable. The company earned $0.02 a share in Q1, and analysts expect profitability to grow. 
Via MarketBeat

Performance

YTD
-33.19%
-33.19%
1 Month
-15.62%
-15.62%
3 Month
-30.96%
-30.96%
6 Month
-35.03%
-35.03%
1 Year
+170.42%
+170.42%

More News

Read More
What 7 Analyst Ratings Have To Say About Amylyx Pharma
Via Benzinga
Analyst Expectations for Amylyx Pharma's Future
Via Benzinga
2 Supercharged Growth Stocks to Buy Right Now
Via The Motley Fool
Amylyx Pharma Earnings Preview
Via Benzinga
Analyst Ratings for Amylyx Pharma
Via Benzinga
Expert Ratings for Amylyx Pharma
Via Benzinga
Looking Into Amylyx Pharmaceuticals's Return On Capital Employed
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
US Stock Futures Signal Strong Finish To Wobbly Week — But Analyst Still Sees Recession Risk On Horizon
Via Benzinga
Amylyx Blows Past Sales Expectations, Reports Unexpected Profit — Shares Rocket
Via Investor's Business Daily
Amylyx Pharmaceuticals Reports First Quarter 2023 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Analyst Expectations for Amylyx Pharma's Future
Via Benzinga
Why Amylyx Pharmaceuticals Stock Is Bolting Higher Today
Via The Motley Fool
Amylyx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
3 Biotechs That Might Get Bought Out in 2023
Via The Motley Fool
Amylyx Pharmaceuticals Appoints Masako Nakamura to General Manager and Head of International Markets - Asia Pacific and Latin America
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 2 Study of AMX0035 for the Treatment of Wolfram Syndrome
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals - An Emerging Leader In ALS
Via Talk Markets
Amylyx Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
7 Biotech Stocks to Buy for 100% Returns
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023
Via Benzinga
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
Via Investor's Business Daily
Why RAPT Therapeutics Shares Are Trading Lower By Over 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.